Cellectis announces the closing of the sale of its Swedish subsidiary Cellectis AB to Takara Bio Inc.
Published on September 04, 2014
September 4, 2014 – Paris (France) – Cellectis (Alternext: ALCLS.PA) a leader in the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART) today announces that it has closed the sale of its subsidiary Cellectis AB to Takara Bio Inc.
The financials terms have not been disclosed.
The Company now concentrates its activities in the field of oncology through the development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy products generated through its allogeneic CAR-T platform, both on its own as well as in partnership with Servier and Pfizer.